WallStSmart

Caris Life Sciences, Inc. Common Stock (CAI)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Caris Life Sciences, Inc. Common Stock generates 34% more annual revenue ($812.03M vs $606.42M). INSM leads profitability with a -2.1% profit margin vs -8.4%. CAI earns a higher WallStSmart Score of 41/100 (D).

CAI

Hold

41

out of 100

Grade: D

Growth: 8.0Profit: 5.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -7.64

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CAI2 strengths · Avg: 10.0/10
Operating MarginProfitability
30.2%10/10

Strong operational efficiency at 30.2%

Revenue GrowthGrowth
125.4%10/10

Revenue surging 125.4% year-over-year

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

CAI4 concerns · Avg: 3.0/10
Price/BookValuation
9.1x4/10

Trading at 9.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-45.4%2/10

ROE of -45.4% — below average capital efficiency

Altman Z-ScoreHealth
-7.642/10

Distress zone — elevated risk

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CAI

The strongest argument for CAI centers on Operating Margin, Revenue Growth. Revenue growth of 125.4% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : CAI

The primary concerns for CAI are Price/Book, EPS Growth, Return on Equity.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

CAI profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

CAI is growing revenue faster at 125.4% — sustainability is the question.

CAI generates stronger free cash flow (29M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CAI scores higher overall (41/100 vs 39/100) and 125.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Caris Life Sciences, Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The company is headquartered in San Francisco, California.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?